Entopsis has developed NuTec — a proprietary glass slide technology with a unique chemical architecture that transforms the complex molecular signatures in urine into actionable diagnostic insights. Non-invasive. Highly accurate. Chemistry impossible to reverse-engineer.
For decades, blood-based diagnostics like the PSA test have been the gold standard. But the data tells a different story.
Grail's Galleri blood test — once valued at billions and advertised at the Super Bowl — failed its primary endpoint in a major NHS study involving hundreds of thousands of participants.
"The test failed to show statistically significant reduction in advanced cancers... results are likely to fuel debate about the technology."— STAT News, Feb 2026
Urine contains unique biomarkers that blood simply cannot capture — making it the ideal medium for non-invasive, early-stage cancer detection.
Prostate-specific gene overexpressed 60-100x in cancer cells. Only detectable in urine after prostate massage — not present in blood.
AUC: 0.706-0.800Gene fusion found in ~50% of prostate cancers. Urinary detection correlates directly with tumor presence — blood testing is far less sensitive.
Specificity: 93%Nano-vesicles shed directly by prostate cells carrying tumor-specific proteins and RNA. ExoDx test achieves 98% NPV without requiring DRE.
NPV: 89-98%Urine concentrates metabolic byproducts — including branched-chain amino acids, pseudouridine, and sarcosine — that reveal cancer metabolic shifts.
23+ Unique MarkersNUTEC stands for Nanoscale Unbiased Textured Capture — a revolutionary platform that transforms complex chemical information into visual diagnostic patterns.
A small urine sample is applied to the NuTec array — a proprietary polymer surface with distinct physicochemical binding regions.
Upon heating, photoinitiators trigger reactions between sample molecules and the array, creating a unique pattern of colored spots.
Machine learning algorithms analyze the colorimetric signature — captured via scanner or smartphone — to identify disease states.
The system outputs a probability score for multiple conditions simultaneously — one test, many diseases.
The NuTec array's power lies in its physical chemistry — the precise formulation of polymer spots, photoinitiators, and binding agents on the glass slide. This molecular architecture is classified as NP-hard to reverse-engineer. Competitors cannot simply analyze the output patterns to recreate the slide's proprietary chemistry, protecting Entopsis's core innovation.
Unlike targeted tests, NuTec reacts with DNA, RNA, proteins, AND small molecules simultaneously. It asks "Is there a problem?" rather than testing for one specific disease.
One platform, many assays. The same NuTec device can diagnose lung, prostate, breast, liver, colorectal cancers, and even Hepatitis B from a single sample.
Published in the Royal Society of Chemistry's Analyst journal and featured on the cover.
The first urine-based multi-marker test that identifies clinically significant prostate cancer with unprecedented accuracy.
Prostate cancer is the second most common cancer in men worldwide. Yet the current standard of care — the PSA blood test — has fundamental limitations:
Accurately identifies that cancer is prostate-specific, not just elevated markers
Same test screens for lung, breast, liver, and colorectal cancers
Affordable enough for regular screening, enabling true early detection
Simple urine sample — no needles, no DRE required
Founded by PhD scientists trained under Nobel laureates and cancer research pioneers.
PhD from Johns Hopkins University. Graduate research on cancer immunotherapy under Dr. Donald Small. Post-doctoral research at Stanford on small molecule inhibitors for leukemia. Former Research Scientist at Exelixis and Chief Scientific Officer at Conversant Biologics.
PhD from Johns Hopkins under Bert Vogelstein, MD — one of the most cited cancer researchers in history. Award recipient at Collegiate Inventors Competition. Currently Principal Investigator at Temasek Life Sciences Laboratory, Singapore.
PhD from Johns Hopkins under Nobel Laureate Peter Agre. Former Senior Analyst at Sabretooth Capital hedge fund. Former SVP Business Development at Retrophin Inc. Co-founded Bridge Tower real estate fund.
PhD from Florida International University in polymeric nanoparticle drug delivery. Led Entopsis to achieve dual ISO certification (ISO 9001:2015 and ISO 13485:2016) for medical device manufacturing.
Quality Management Certified
Medical Device Certified
Royal Society of Chemistry
Thiel Foundation Backed
"The versatility of NuTec is unprecedented. This platform has the potential to transform how we detect the world."
"An entirely new way to analyze biomolecules... could become the new paradigm for rapid molecular identification."
Join the revolution in non-invasive diagnostics. Whether you're a researcher, investor, clinician, or institution — let's discuss how Entopsis can advance your mission.